Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capmatinib + Erlotinib in EGFR-mutated cMET-amplified NSCLC
NCT02468661Phase 1Terminated
- Sponsor
- Novartis
- Start
- Sep 2015
- Primary completion
- Nov 2017
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 10
01
Overview
Phase 1, open-label trial of capmatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Novartis. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Sep 2015; status: terminated.
02
Drugs
capmatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02468661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02468661.